The Effects of Tadalafil on Cold-induced Vasoconstriction in Patients with Raynaud's Phenomenon
- 14 February 2007
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 81 (4) , 503-509
Abstract
Raynaud's phenomenon (RP) is a disorder characterized by episodic periods of vasoconstriction typically provoked by exposure to cold. Phosphodiesterase 5 (PDE5) inhibitors may improve digital blood flow and clinical symptoms in patients with RP, but the mechanisms are unknown. We examined the hypothesis that a PDE5 inhibitor, tadalafil, attenuates cold-induced vasoconstriction. Additionally, we examined whether tadalafil reduced vascular dysfunction following ischemia, thus altering the response to repeated cooling. We conducted a double-blind, placebo-controlled crossover study in 20 subjects with RP on two separate study days, when subjects received either placebo or tadalafil (10 mg). Digital blood flow (flux) was measured by laser Doppler flowmetry at rest and during two graduated local heat and cold exposure cycles. Temperature-response curves were evaluated by E(max) (maximal flux during heating), E(min) (minimal flux during cooling), and ET(50) and ET(90) (the local temperature at which flux decreased by 50% and 90% of E(max)-E(min), respectively). Tadalafil did not increase baseline flux (81.0+/-73.0 vs 91.3+/-114.0 arbitrary unit (AU), P=0.57), E(max) (280.0+/-107.6 vs 279.5+/-119.8 AU, P=0.94), ET(50) (25.4+/-4.4 vs 26.6+/-5.7 degrees C, P=0.62), or ET(90) (21.2+/-3.9 vs 21.8+/-5.0 degrees C, P=0.78), (cycle 1 values presented). There were no differences between cycles on either study day. In conclusion, in patients with RP, single-dose tadalafil does not increase digital blood flow at baseline or in response to heating, nor does it attenuate cold-induced vasoconstriction. Furthermore, it does not precondition the endothelium to resist a second cooling challenge. The clinical benefit in patients with RP treated with PDE5 inhibitors probably involves mechanisms other than acute inhibition of cold-induced vasoconstriction.Keywords
This publication has 26 references indexed in Scilit:
- Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafilMicrovascular Research, 2005
- The incidence and natural history of Raynaud's phenomenon in the communityArthritis & Rheumatism, 2005
- Severe digital ischaemia treated with phosphodiesterase inhibitorsAnnals of the Rheumatic Diseases, 2004
- Langzeiteffekte von Sildenafil bei Sklerodermie-assoziierter pulmonaler Hypertonie und Raynaud-SyndromDMW - Deutsche Medizinische Wochenschrift, 2004
- The vasculopathy of Raynaud's phenomenon and sclerodermaRheumatic Disease Clinics of North America, 2003
- Seasonal differences in finger skin temperature and microvascular blood flow in healthy men and women are exaggerated in women with primary Raynaud's phenomenonBritish Journal of Clinical Pharmacology, 2001
- Non-Invasive Investigation of Endothelium-Dependent Dilatation of the Brachial Artery in Women with Primary Raynaud's PhenomenonClinical Science, 1998
- Effects of activation method on the pore structure of activated carbons from apricot stonesCarbon, 1996
- Cold exposure increases cyclic guanosine monophosphate in healthy women but not in women with Raynaud's phenomenonJournal of Internal Medicine, 1995
- Venodilation in Raynaud's diseaseThe Lancet, 1993